440 completed, 113 terminated, 34 active not recruiting, 19 withdrawn. 286 Phase 2, 264 Phase 1, 90 Phase 3, 8 Phase 4, 4 Not applicable.
By phase and status
| Phase | Trials | Status |
|---|
| Phase 2 | 286 | Completed 179, Terminated 55, Active not recruiting 21, Withdrawn 11, Recruiting 10, Unknown 8, Enrolling by invitation 1, Suspended 1 |
| Phase 1 | 264 | Completed 182, Terminated 58, Active not recruiting 9, Withdrawn 7, Recruiting 3, Not yet recruiting 2, Unknown 2, Suspended 1 |
| Phase 3 | 90 | Completed 63, Terminated 9, Active not recruiting 8, Recruiting 4, Unknown 3, Withdrawn 3 |
| Phase 4 | 8 | Completed 7, Unknown 1 |
| Not applicable | 4 | Completed 2, Terminated 1, Unknown 1 |
| Early Phase 1 | 1 | Terminated 1 |
Follow this sponsor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Evaluate the Blood Levels, Safety, and Tolerability of BMS-986368 in Healthy Chinese Participants
BMS-986368, BMS-986368-matching Placebo - Healthy Volunteers | Phase 1 | Not yet recruiting | Celgene | 16 | 2027-01-05 | 2026-07-14 |
A Study to Assess the Relative Bioavailability of Irafamdastat (BMS-986368) and to Assess the Food Effect on the Pharmacokinetics of Irafamdastat in Healthy Adult Participants
Irafamdastat - Healthy Volunteers | Phase 1 | Not yet recruiting | Celgene | 24 | 2026-10-06 | 2026-09-23 |
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants
BMS-986365, Itraconazole, Rifampin - Healthy Volunteers | Phase 1 | Terminated | Celgene | 22 | 2025-12-15 | 2026-07-20 |
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Elranatamab, Mezigdomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Celgene | 62 | 2025-10-07 | 2026-09-02 |
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Golcadomide, Rituximab, Lenalidomide - Follicular Lymphoma | Phase 3 | Recruiting | Celgene | 400 | 2025-07-28 | 2026-05-20 |
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
BMS-986368, Placebo - Agitation, Alzheimer Disease | Phase 2 | Recruiting | Celgene | 120 | 2025-06-09 | 2026-10-06 |
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
BMS-986368, Placebo - Multiple Sclerosis Spasticity | Phase 2 | Recruiting | Celgene | 200 | 2025-06-05 | 2026-10-01 |
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
BMS-986365, Enzalutamide, Abiraterone - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Active not recruiting | Celgene | 960 | 2025-03-13 | 2026-09-30 |
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Elotuzumab, Iberdomide, Dexamethasone - Myeloma, Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Omar Nadeem, MD | 49 | 2024-11-01 | 2026-10-07 |
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
Golcadomide, Rituximab, Cyclophosphamide - Lymphoma, Follicular | Phase 2 | Active not recruiting | Celgene | 95 | 2024-08-30 | 2026-07-31 |
Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
BMS-986369 - Hepatic Impairment, Healthy Volunteers | Phase 1 | Completed | Celgene | 29 | 2024-08-15 | 2026-01-23 |
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
Golcadomide, Placebo, Rituximab - Large B-cell Lymphoma | Phase 3 | Active not recruiting | Celgene | 850 | 2024-06-19 | 2026-07-06 |
A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity
BMS-986368 - Healthy Participants | Phase 1 | Completed | Celgene | 56 | 2024-05-31 | 2024-11-12 |
A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants
BMS-986365, [14C] BMS-986365, [14C] BMS-986409 + BMS-986410 - Healthy Volunteers | Phase 1 | Completed | Celgene | 24 | 2024-05-30 | 2025-03-26 |
Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants
BMS-986365, Rabeprazole - Healthy Participants | Phase 1 | Completed | Celgene | 102 | 2024-05-28 | 2025-03-06 |
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Alnuctamab, Pomalidomide, Daratumumab - Multiple Myeloma | Phase 3 | Withdrawn | Celgene | | 2024-05-03 | 2024-05-31 |
A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants
Itraconazole, Rifampin, Golcadomide - Healthy Volunteers | Phase 1 | Completed | Celgene | 35 | 2024-04-23 | 2024-09-27 |
A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment
Mezigdomide - Renal Impairment | Phase 1 | Completed | Celgene | 26 | 2024-03-21 | 2025-06-04 |
A Study to Assess the Effects of Itraconazole, Food, and pH on the Drug Levels of BMS-986368 in Healthy Participants
BMS-986368, Itraconazole, Famotidine - Healthy Participants | Phase 1 | Completed | Celgene | 32 | 2024-03-18 | 2024-07-01 |
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
Alnuctamab, Mezigdomide, Dexamethasone - Multiple Myeloma | Phase 1 | Terminated | Celgene | 4 | 2024-02-27 | 2026-04-21 |
Showing 20 of 652. Sign in to see all of them.
Conditions studied
Multiple Myeloma (141) · Recurrence (72) · Myelodysplastic Syndromes (62) · Leukemia, Myeloid, Acute (49) · Lymphoma (38) · Lymphoma, Non-Hodgkin (30) · Neoplasms (26) · Carcinoma, Non-Small-Cell Lung (24) · Leukemia (24) · Lymphoma, Large B-Cell, Diffuse (24) · Breast Neoplasms (22) · Leukemia, Lymphocytic, Chronic, B-Cell (21) · Pancreatic Neoplasms (21) · Lymphoma, Follicular (19) · Neoplasms, Plasma Cell (19)
Interventions
Lenalidomide (144) · Dexamethasone (85) · Azacitidine (60) · Albumin-Bound Paclitaxel (57) · pomalidomide (55) · 130-nm albumin-bound paclitaxel (48) · Gemcitabine (35) · Rituximab (34) · ozanimod (27) · Cyclophosphamide (25) · Calcium Dobesilate (24) · romidepsin (22) · cc-486 (20) · Carboplatin (19) · Prednisone (19)
Countries
United States (454) · Spain (157) · France (138) · Germany (130) · United Kingdom (130) · Italy (125) · Canada (120) · Belgium (81) · Australia (74) · Netherlands (64) · Austria (62) · Poland (62) · Japan (58) · Greece (56) · Sweden (48)
Top investigators
Leon Carayannopoulos, MD (11) · Edward O'Mara, MD (9) · Robert Knight, MD (8) · Jonathan Tran, Pharm.D (7) · Amar Patel, MD (5) · Maria Palmisano, MD (5) · Steven D Reich, MD (5) · Ileana Elias, MD (4) · Toru Sasaki (4) · Amine Bensmaine, MD (3) · Bouchra Benettaib, MD (3) · Francisco Ramirez-Valle, MD, PhD (3) · Guillermo Rossiter, MD (3) · Ileana Elias, M.D. (3)
Results publications
PMID 36208720, PMID 39018016, PMID 34515338, PMID 35549810, PMID 38507688, PMID 41677183, PMID 17021321, PMID 18799726, PMID 19901114, PMID 20705560, PMID 21273172, PMID 23834234, PMID 33197925, PMID 33218965, PMID 33687069, PMID 34247273, PMID 34587246, PMID 37704579, PMID 37705327, PMID 38031761, PMID 38040274, PMID 38048552, PMID 38723981, PMID 38796193, PMID 39293025, PMID 39319495, PMID 39773524, PMID 40462564, PMID 41003640, PMID 41058119, PMID 41857682, PMID 16859580, PMID 18032762, PMID 18032763, PMID 19230772, PMID 19470941, PMID 19705057, PMID 20026804, PMID 20136825, PMID 20142433, PMID 20171147, PMID 20394651, PMID 20421455, PMID 20451404, PMID 20697094, PMID 21079611, PMID 21130701, PMID 21228334, PMID 21495023, PMID 21656747
NIH funding
2017 (13), 2023 (11), 2014 (10), 2015 (10), 2018 (10), 2019 (10), 2016 (7), 2009 (4), 2008 (2), P30CA060553 (2), P30CA093373 (2), 2004 (1), 2005 (1), 2025 (1), P30CA006516 (1)